Cannabinoids and monoamine neurotransmission with focus on monoamine oxidase

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 38, Issue 1, 2012, Pages 68-77

  Fišar, Zdeněk ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cannabinoid; Mental disorder; Monoamine neurotransmitter; Monoamine oxidase; Neuroplasticity

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ANANDAMIDE; ANTIDEPRESSANT AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; ENDOCANNABINOID; IPRONIAZID; MONOAMINE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TYRAMINE;

ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; BEER; CANNABIS ADDICTION; CHEESE; DEGENERATIVE DISEASE; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; FERMENTED PRODUCT; FOOD; FOOD DRUG INTERACTION; HUMAN; MONOAMINE METABOLISM; MONOAMINERGIC SYSTEM; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENERGIC SYSTEM; OXIDATIVE STRESS; PANIC; PARKINSON DISEASE; REWARD; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; WINE;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; CANNABINOIDS; MENTAL DISORDERS; MONOAMINE OXIDASE; NEURONAL PLASTICITY; SYNAPTIC TRANSMISSION;

EID: 84862861718     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.12.010     Document Type: Article

References (166)

1. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999, 58:315-348.
2. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
3. Bach A.W.J., Lan N.C., Johnson D.L., Abell C.W., Bembenek M.E., Kwan S.-W., et al. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A 1988, 85:4934-4938.
4. Bambico F.R., Duranti A., Tontini A., Tarzia G., Gobbi G. Endocannabinoids in the treatment of mood disorders: evidence from animal models. Curr Pharm Des 2009, 15(14):1623-1646.
5. 9-tetrahydrocannabinol on monoamine oxidase activity of rat tissues in vivo. Biochem Pharmacol 1975, 24:1435-1436.
6. 9-tetrahydrocannabinol on membrane-bound monoamine oxidase activity. Toxicol Appl Pharmacol 1977, 40:347-354.
7. 3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 2002, 137(5):589-596.
8. Barg J., Fride E., Hanus L., Levy R., Matus-Leibovitch N., Heldman E., et al. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol 1995, 287:145-152.
9. Bazinet R.P., Lee H.J., Felder C.C., Porter A.C., Rapoport S.I., Rosenberger T.A. Rapid high-energy microwave fixation is required to determine the anandamide (N-arachidonoylethanolamine) concentration of rat brain. Neurochem Res 2005, 30:597-601.
10. 1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behav Pharmacol 2005, 16:275-296.
11. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 2002, 83:1241-1251.
12. Bodor A.L., Katona I., Nyíri G., Mackie K., Ledent C., Hájos N., et al. Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci 2005, 25:6845-6856.
13. Bolla K.I., Brown K., Eldreth D., Tate K., Cadet J.L. Dose-related neurocognitive effects of marijuana use. Neurology 2002, 59:1337-1343.
14. Bosier B., Muccioli G.G., Hermans E., Lambert D.M. Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 2010, 80(1):1-12.
15. Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med 2005, 352(11):1112-1120.
16. 9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 2007, 555:156-163.
17. 9-tetrahydrocannabinol. J Neurochem 2005, 93:802-811.
18. Centonze D., Finazzi-Agrò A., Bernardi G., Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 2007, 28:180-187.
19. Chakrabarty I., Sengupta D., Bhattacharya P., Ghosh J.J. Effect of cannabis extract on the uterine monoamine oxidase activity of normal and estradiol treated rats. Biochem Pharmacol 1976, 25:377-378.
20. Cheer J.F., Wassum K.M., Sombers L.A., Heien M.L., Ariansen J.L., Aragona B.J., et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 2007, 27:791-795.
21. Chevaleyre V., Takahashi K.A., Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 2006, 29:37-76.
22. Citri A., Malenka R.C. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 2008, 33(1):18-41.
23. Clarke D.E., Jandhyala B. Acute and chronic effects of tetrahydrocannabinols on monoamide oxidase activity: possible vehicle/tetrahydrocannabinol interactions. Res Commun Chem Pathol Pharmacol 1977, 17:471-480.
24. Cone E.J., Huestis M.A. Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit 1993, 15:527-532.
25. Dalton G.D., Bass C.E., Van Horn C.G., Howlett A.C. Signal transduction via cannabinoid receptors. CNS Neurol Disord Drug Targets 2009, 8(6):422-431.
26. D'Ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992, 35:124-135.
27. Degenhardt L., Hall W. Cannabis and psychosis. Curr Psychiatry Rep 2002, 4:191-196.
28. Degenhardt L., Hall W. Is cannabis use a contributory cause of psychosis?. Can J Psychiatry 2006, 51:556-565.
29. Demuth D.G., Molleman A. Cannabinoid signalling. Life Sci 2006, 78(6):549-563.
30. Devane W.A., Dysarz F.A. III., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34:605-613.
31. Devane W.A., Hanuš L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
32. Di Marzo V., Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589.
33. Draganski B., May A. Training-induced structural changes in the adult human brain. Behav Brain Res 2008, 192(1):137-142.
34. D'Souza D.C. Cannabinoids and psychosis. Int Rev Neurobiol 2007, 78:289-326.
35. Duman R.S. Synaptic plasticity and mood disorders. Mol Psychiatry 2002, 7:S29-S34.
36. Duman R.S. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin Neurosci 2009, 11(3):239-255.
37. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59(12):1116-1127.
38. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997, 54:597-606.
39. Edmondson D.E., Binda C., Wang J., Upadhyay A.K., Mattevi A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 2009, 48:4220-4230.
40. Emrich H.M., Leweke F.M., Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997, 56:803-807.
41. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011, 117(2-3):152-157.
42. Fagervall I., Ross S.B. Inhibition of monoamine oxidase in monoaminergic neurones in the rat brain by irreversible inhibitors. Biochem Pharmacol 1986, 35:1381-1387.
43. Faraj B.A., Davis D.C., Camp V.M., Mooney A.J., Holloway T., Barika G. Platelet monoamine oxidase activity in alcoholics, alcoholics with drug dependence, and cocaine addicts. Alcohol Clin Exp Res 1994, 18:1114-1120.
44. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996, 393:231-235.
45. Fergusson D.M., Horwood L.J., Lynskey M.T., Madden P.A. Early reactions to cannabis predict later dependence. Arch Gen Psychiatry 2003, 60:1033-1039.
46. Fišar Z. Phytocannabinoids and endocannabinoids. Curr Drug Abuse Rev 2009, 2(1):51-75.
47. Fišar Z. Cannabinoids and atherosclerosis. Prague Med Rep 2009, 110(1):5-12.
48. Fišar Z. Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 2010, 381(6):563-572.
49. Fišar Z., Hroudová J. Intracellular signalling pathways and mood disorders. Folia Biol 2010, 56(4):135-148.
50. Fišar Z., Raboch J. Depression, antidepressants, and peripheral blood components. Neuro Endocrinol Lett 2008, 29(1):17-28.
51. Fišar Z., Krulík R., Fuksová K., Sikora J. Imipramine distribution among red blood cells, plasma and brain tissue. Gen Physiol Biophys 1996, 15(1):51-64.
52. Fišar Z., Fuksová K., Sikora J., Kališová L., Velenovská M., Novotná M. Distribution of antidepressants between plasma and red blood cells. Neuro Endocrinol Lett 2006, 27(3):307-313.
53. Fišar Z., Hroudová J., Raboch J. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett 2010, 31(5):645-656.
54. Fowler P.W., Balali-Mood K., Deol S., Coveney P.V., Sansom M.S. Monotopic enzymes and lipid bilayers: a comparative study. Biochemistry 2007, 46:3108-3115.
55. Gaoni Y., Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964, 86:1646-1647.
56. García-Junco-Clemente P., Linares-Clemente P., Fernández-Chacón R. Active zones for presynaptic plasticity in the brain. Mol Psychiatry 2005, 10(2):185-200.
57. 9-tetrahydrocannabinol on monoamine oxidase activity in bovine eye tissues, in vitro. Invest Ophthalmol Vis Sci 1982, 22:482-485.
58. Goodman A. Neurobiology of addiction. An integrative review. Biochem Pharmacol 2008, 75:266-322.
59. Gorzalka B.B., Hill M.N., Hillard C.J. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 2008, 32:1152-1160.
60. Grant I., Gonzalez R., Carey C.L., Natarajan L., Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003, 9:679-689.
61. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007, 4:1744-1769.
62. Haefely W., Burkard W.P., Cesura A.M., Kettler R., Lorez H.P., Martin J.R., et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl) 1992, 106(Suppl 1):S6-S14.
63. Hall W., Solowij N. Adverse effects of cannabis. Lancet 1998, 352:1611-1616.
64. Haller J., Mátyás F., Soproni K., Varga B., Barsy B., Németh B., et al. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 2007, 25:2445-2456.
65. Hampson A.J., Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci 2001, 13:1529-1536.
66. Haney M., Hart C.L., Ward A.S., Foltin R.W. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl) 2003, 165:157-165.
67. Hasan F., McCrodden J.M., Kennedy N.P., Tipton K.F. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm Suppl 1988, 26:1-9.
68. Hershkowitz M. The effect of in vivo treatment with (-) delta 1-tetrahydrocannabinol, and other psychoactive drugs on the in vitro uptake of biogenic amines. Adv Biosci 1978, 22-23:351-358.
69. Hill M.N., Gorzalka B.B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets 2009, 8(6):451-458.
70. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005, 30:508-515.
71. Hill M.N., Sun J.C., Tse M.T., Gorzalka B.B. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int J Neuropsychopharmacol 2006, 9(3):277-286.
72. Hill M.N., Ho W.S., Hillard C.J., Gorzalka B.B. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J Neural Transm 2008, 115:1673-1679.
73. Hillard C.J., Jarrahian A. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 2000, 108:123-134.
74. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006, 13:1170-1185.
75. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
76. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Porrino L.J. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004, 47(Suppl 1):345-358.
77. Hroudová J., Fišar Z. Connectivity between mitochondrial functions and psychiatric disorders. Psychiatry Clin Neurosci 2011, 65(2):130-141.
78. Hyman S.E., Malenka R.C., Nestler E.J. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006, 29:565-598.
79. Iversen L. Cannabis and the brain. Brain 2003, 126:1252-1270.
80. Jans L.A.W., Riedel W.J., Markus C.R., Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry 2007, 12:522-543.
81. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005, 115:3104-3116.
82. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001, 178:116-122.
83. Kato T. Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications. CNS Drugs 2007, 21(1):1-11.
84. Kato T. Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 2008, 44(1):92-102.
85. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000, 2(3 Pt 1):180-190.
86. Kenney S.P., Kekuda R., Prasad P.D., Leibach F.H., Devoe L.D., Ganapathy V. Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. Am J Obstet Gynecol 1999, 181:491-497.
87. Kim S.H., Won S.J., Mao X.O., Jin K., Greenberg D.A. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol 2006, 69:691-696.
88. Koethe D., Hoyer C., Leweke F.M. The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl) 2009, 206(4):551-561.
89. Koob G.F., Le Moal M. Neurobiology of addiction 2006, 289-337. Elsevier.
90. Lambert D.M., Fowler C.J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005, 48:5059-5087.
91. Laviolette S.R., Grace A.A. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 2006, 63:1597-1613.
92. Leweke F.M., Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008, 13(2):264-275.
93. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999, 10:1665-1669.
94. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 2007, 94:29-36.
95. Lovinger D.M. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 2008, 184:435-477.
96. Maccarrone M., Bari M., Finazzi-Agrò A. Quantification of anandamide content in animal cells and tissues: the normalization makes the difference. Lipids Health Dis 2002, 1:4.
97. Maccarrone M., Battista N., Centonze D. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog Neurobiol 2007, 81:349-379.
98. Macleod J., Oakes R., Copello A., Crome I., Egger M., Hickman M., et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004, 363:1579-1588.
99. Macleod J., Davey Smith G., Hickman M. Does cannabis use cause schizophrenia?. Lancet 2006, 367:1055.
100. Macleod J., Davey Smith G., Hickman M., Egger M. Cannabis and psychosis. Lancet 2007, 370:1539.
101. Maejima T., Ohno-Shosaku T., Kano M. Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neurosci Res 2001, 40:205-210.
102. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24(1):27-53.
103. Malberg J.E., Blendy J.A. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005, 26:631-638.
104. Mangieri R.A., Piomelli D. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol Res 2007, 56:360-366.
105. Marsicano G., Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest 2006, 29(3 Suppl):27-46.
106. Mazor M., Dvilansky A., Aharon M., Lazarovitz Z., Nathan I. Effect of cannabinoids on the activity of monoamine oxidase in normal human platelets. Arch Int Physiol Biochim 1982, 90:15-20.
107. McBain C.J., Kauer J.A. Presynaptic plasticity: targeted control of inhibitory networks. Curr Opin Neurobiol 2009, 19(3):254-262.
108. 1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965, 87:3273-3275.
109. Mechoulam R., Ben-Shabat S., Hanuš L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83-90.
110. Mendiguren A., Pineda J. Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats. Eur J Pharmacol 2006, 534:83-88.
111. Mesulam M.M. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999, 24(3):521-529.
112. Meyer J.H., Ginovart N., Boovariwala A., Sagrati S., Hussey D., Garcia A., et al. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006, 63:1209-1216.
113. Meyer J.H., Wilson A.A., Sagrati S., Miler L., Rusjan P., Bloomfield P.M., et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry 2009, 66(12):1304-1312.
114. 9-tetrahydrocannabinol treatments. Neurochem Res 1993, 18:1183-1191.
115. 9-tetrahydrocannabinol on developing serotonergic system. Eur J Pharmacol 1996, 316:39-42.
116. 9-THC) alters indolamine levels and turnover in adult male and female rat brain regions. Brain Res Bull 1997, 43:173-178.
117. 1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 2004, 369(5):516-524.
118. Muccioli G.G., Stella N. An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain. Anal Biochem 2008, 373:220-228.
119. Mura P., Kintz P., Dumestre V., Raul S., Hauet T. THC can be detected in brain while absent in blood. J Anal Toxicol 2005, 29:842-843.
120. Naef M., Russmann S., Petersen-Felix S., Brenneisen R. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci 2004, 93:1176-1184.
121. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
122. 1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 2005, 136:811-822.
123. Oliva J.M., Uriguen L., Perez-Rial S., Manzanares J. Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain. Neuropharmacology 2005, 49:618-626.
124. Onaivi E.S., Benno R., Halpern T., Mehanovic M., Schanz N., Sanders C., et al. Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders. Curr Neuropharmacol 2011, 9(1):209-214.
125. Pacher P., Bátkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
126. Pertwee R.G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005, 7(3):E625-E654.
127. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di Marzo V., Elphick M.R., et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB[U+2082]. Pharmacol Rev 2010, 62(4):588-631.
128. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003, 4:873-884.
129. Pope H.G., Gruber A.J., Hudson J.I., Huestis M.A., Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001, 58:909-915.
130. Pope H.G., Gruber A.J., Hudson J.I., Cohane G., Huestis M.A., Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association?. Drug Alcohol Depend 2003, 69:303-310.
131. 3 receptor function. Eur J Pharmacol 2005, 517(1-2):68-73.
132. Ramsay R.R., Gravestock M.B. Monoamine oxidases: to inhibit or not to inhibit. Mini Rev Med Chem 2003, 3:129-136.
133. Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006, 361:1545-1564.
134. Reid M.J., Bornheim L.M. Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochem Pharmacol 2001, 61:1357-1367.
135. Riederer P., Danielczyk W., Grünblatt E. Monoamine oxidase-B inhibition in Alzheimer's disease. Neurotoxicology 2004, 25:271-277.
136. Rubino T., Sala M., Viganò D., Braida D., Castiglioni C., Limonta V., et al. Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology 2007, 32:2036-2045.
137. Russo E.B., Burnett A., Hall B., Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005, 30(8):1037-1043.
138. 9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 2006, 372:313-317.
139. Sarafian T.A., Kouyoumjian S., Khoshaghideh F., Tashkin D.P., Roth M.D. Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am J Physiol Lung Cell Mol Physiol 2003, 284:L298-L306.
140. Sarafian T.A., Habib N., Oldham M., Seeram N., Lee R.P., Lin L., et al. Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol 2006, 290:L1202-L1209.
141. 1-tetrahydrocannabinol, inhibits human brain and liver monoamine oxidase. Gen Pharmacol 1984, 15:171-174.
142. Seely K.A., Prather P.L., James L.P., Moran J.H. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?. Mol Interv 2011, 11(1):36-51.
143. 11C]DASB. Psychopharmacology (Berl) 2011, 213(2-3):555-562.
144. Solowij N., Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 2008, 1:81-98.
145. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J Psychiatry Neurosci 2007, 32:30-52.
146. Stahl S.M., Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008, 13:855-870.
147. Stefanis N.C., Delespaul P., Henquet C., Bakoula C., Stefanis C.N., Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004, 99:1333-1341.
148. +-ATPase. Neurochem Int 2004, 44:529-538.
149. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 388:773-778.
150. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005, 10:900-919.
151. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
152. Tanda G., Goldberg S.R. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacology (Berl) 2003, 169:115-134.
153. 1 opioid receptor mechanism. Science 1997, 276:2048-2050.
154. Tasker J.G. Rapid glucocorticoid actions in the hypothalamus as a mechanism of homeostatic integration. Obesity (Silver Spring) 2006, 14(Suppl 5):259S-265S.
155. Tóth K., McBain C.J. Target-specific expression of pre- and postsynaptic mechanisms. J Physiol 2000, 525(1):41-51.
156. 1 cannabinoid receptor. J Mol Endocrinol 2010, 44(2):75-85.
157. Ujike H., Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 2004, 96:376-381.
158. Ujike H., Takaki M., Nakata K., Tanaka Y., Takeda T., Kodama M., et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002, 7:515-518.
159. Vardakou I., Pistos C., Spiliopoulou Ch. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010, 197(3):157-162.
160. Velenovská M., Fišar Z. Effect of cannabinoids on platelet serotonin uptake. Addict Biol 2007, 12:158-166.
161. Viveros M.-P., Marco E.-M., Llorente R., López-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007, 2007(52908):1-12.
162. Viveros M.P., de Fonseca F.R., Bermudez-Silva F.J., McPartland J.M. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocr Metab Immune Disord Drug Targets 2008, 8:220-230.
163. Youdim M.B., Bakhle Y.S. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 2006, 147(Suppl 1):S287-S296.
164. Youdim M.B., Edmondson D., Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006, 7:295-309.
165. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002, 325:1199-1201.
166. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int 2009, 106(27):464-467.